🧬 European Biotech Act Q&A - Engage Directly with the Policymakers
​The publication of the European Biotech Act marks a historic milestone: for the first time, biotechnology is formally recognised as a strategic priority for Europe. As this landmark initiative moves from vision to implementation, meaningful dialogue between policymakers, experts, and the biotech community is more important than ever.
​To support this exchange, the European Synthetic Biology Society (EUSynBioS) is hosting a dedicated Q&A session and policy panel with professionals directly involved in shaping European and international biotech policy. This event offers a unique opportunity to ask questions, gain first-hand insights into the Biotech Act, and understand what it means for innovation, healthcare, biosecurity, and the future convergence of AI and synthetic biology.
​The discussion will explore:
​The objectives and scope of the European Biotech Act
​Implications for healthcare innovation, critical medicines, and biomanufacturing
​Biosecurity considerations alongside expanding biotech capacity
​The convergence of AI and synthetic biology and how it is being addressed in policy
​What the next steps in implementation may look like
​
🎤 Speakers
​Daniel Nadal - Policy Analyst, Science, Technology and Innovation Directorate (DSTI), OECD
Daniel works at the OECD facilitating multistakeholder dialogue and translating expert knowledge into policy on emerging technologies, with a strong focus on the responsible innovation of synthetic biology. He previously worked in EU government affairs at Johnson & Johnson in Brussels and has held roles at the European Commission, the United Nations, and healthtech startups. Daniel holds a Master’s degree in International Public Policy from University College London and a Bachelor’s degree in Biochemistry from Imperial College London.
​Joeri Boterman - Policy Officer, DG SANTE, European Commission
Joeri is part of the European Commission team working directly on the European Biotech Act within DG SANTE. Prior to joining the Commission, he served as Belgium’s Pharma & Health Attaché at the Council of the European Union and held roles at the Belgian Federal Agency for Medicines and Health Products (FAMHP) as well as in the private sector, specialising in EU healthcare and vaccine policy.
​This session is open to researchers, industry professionals, policymakers, students, and all stakeholders interested in Europe’s biotechnology future. Participants are encouraged to submit questions in advance to help shape a dynamic and relevant discussion.
​Join us as we engage with the people behind the policy and ensure that Europe’s biotech community has a strong, informed voice as the European Biotech Act moves forward.